Malcolm Boyce

3.3k total citations
107 papers, 2.4k citations indexed

About

Malcolm Boyce is a scholar working on Surgery, Molecular Biology and Epidemiology. According to data from OpenAlex, Malcolm Boyce has authored 107 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Surgery, 20 papers in Molecular Biology and 19 papers in Epidemiology. Recurrent topics in Malcolm Boyce's work include Helicobacter pylori-related gastroenterology studies (22 papers), Neuroendocrine Tumor Research Advances (13 papers) and Gastroesophageal reflux and treatments (11 papers). Malcolm Boyce is often cited by papers focused on Helicobacter pylori-related gastroenterology studies (22 papers), Neuroendocrine Tumor Research Advances (13 papers) and Gastroesophageal reflux and treatments (11 papers). Malcolm Boyce collaborates with scholars based in United Kingdom, United States and Norway. Malcolm Boyce's co-authors include Steve Warrington, Kathy Baisley, Peter J. Barnes, Brian O’Connor, Trevor T. Hansel, D. Mark Pritchard, Andrea Varró, Stephen T. Holgate, Alexis Rames and Louis M. Renzetti and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Malcolm Boyce

105 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Malcolm Boyce United Kingdom	29	560	500	468	428	396	107	2.4k
Richard H. Turnage United States	33	361 0.6×	1.1k 2.3×	505 1.1×	230 0.5×	478 1.2×	81	3.0k
Masayuki Furukawa Japan	25	268 0.5×	422 0.8×	424 0.9×	363 0.8×	507 1.3×	127	2.1k
Albrecht Hoffmeister Germany	28	346 0.6×	1.1k 2.2×	509 1.1×	576 1.3×	457 1.2×	143	2.7k
Hiromi Iwagaki Japan	28	208 0.4×	619 1.2×	726 1.6×	321 0.8×	393 1.0×	202	2.6k
Akihiro Sekine Japan	31	325 0.6×	440 0.9×	1.5k 3.3×	685 1.6×	568 1.4×	103	4.4k
Nora V. Bergasa United States	32	317 0.6×	905 1.8×	292 0.6×	1.6k 3.6×	809 2.0×	96	4.2k
Tatsuma Okazaki Japan	30	567 1.0×	317 0.6×	1.0k 2.2×	155 0.4×	415 1.0×	64	2.8k
Paul Jordan United States	26	223 0.4×	383 0.8×	481 1.0×	295 0.7×	312 0.8×	90	2.2k
Kunio Dobashi Japan	35	796 1.4×	344 0.7×	1.5k 3.2×	242 0.6×	1.0k 2.5×	163	4.1k
Raffaele Manna Italy	29	463 0.8×	444 0.9×	967 2.1×	485 1.1×	101 0.3×	161	2.7k

Countries citing papers authored by Malcolm Boyce

Since Specialization

Citations

This map shows the geographic impact of Malcolm Boyce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Boyce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Boyce more than expected).

Fields of papers citing papers by Malcolm Boyce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm Boyce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Boyce. The network helps show where Malcolm Boyce may publish in the future.

Co-authorship network of co-authors of Malcolm Boyce

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm Boyce. A scholar is included among the top collaborators of Malcolm Boyce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm Boyce. Malcolm Boyce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bentley, Darren, et al.. (2024). A randomized, double‐blind, placebo‐controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease. Clinical and Translational Science. 18(1). e13901–e13901.

Zitt, Christof, Pierre Fustier, Vaia Stavropoulou, et al.. (2023). Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study. British Journal of Clinical Pharmacology. 89(7). 2295–2303. 3 indexed citations

Chen, Duan, Susan J. Hagen, Malcolm Boyce, & Chun‐Mei Zhao. (2023). Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology. Journal of Neuroendocrinology. 35(11). e13305–e13305. 6 indexed citations

Boyce, Malcolm, et al.. (2021). ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study. British Journal of Clinical Pharmacology. 87(8). 3177–3189. 32 indexed citations

Alten, Rieke, et al.. (2020). Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases. 23(11). 1514–1525. 10 indexed citations

Anderson, Richard A., Ruth Thieroff‐Ekerdt, Malcolm Boyce, et al.. (2020). Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. The Journal of Clinical Endocrinology & Metabolism. 105(12). e4857–e4865. 12 indexed citations

Berg, Frans van den, et al.. (2017). A randomized, double-blind, single dose comparison of pharmacokinetics and safety of FKB238 with bevacizumab.. Journal of Clinical Oncology. 35(15_suppl). e14007–e14007. 2 indexed citations

Mick, Inge, John McGonigle, Mark Bolstridge, et al.. (2017). Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. Biological Psychiatry. 81(11). 941–948. 27 indexed citations

Allen, C., G. Francis, James Martín, & Malcolm Boyce. (2017). Regulatory experience of TOPS: an internet-based system to prevent healthy subjects from over-volunteering for UK clinical trials. European Journal of Clinical Pharmacology. 73(12). 1551–1555. 5 indexed citations

10.

Zimmermann, Tracy, Verena Karsten, Amy Chan, et al.. (2017). Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. Molecular Therapy. 25(1). 71–78. 157 indexed citations

11.

Boyce, Malcolm, Andrew R. Moore, Liv Sagatun, et al.. (2016). Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. British Journal of Clinical Pharmacology. 83(3). 466–475. 47 indexed citations

12.

Boyce, Malcolm, et al.. (2016). Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity. European Journal of Clinical Pharmacology. 73(2). 129–139. 5 indexed citations

13.

Norris, Virginia, Steve Warrington, & Malcolm Boyce. (2015). Effect of Inhaled Interferon Beta-1a on Carbon Monoxide Transfer Factor in Healthy Volunteers. Journal of Interferon & Cytokine Research. 36(2). 113–119. 1 indexed citations

14.

Kim, John, Malcolm Boyce, Steve Warrington, et al.. (2015). Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men. Xenobiotica. 45(8). 663–671. 1 indexed citations

15.

Wilson, Robert C., Anthony Cahn, Jonathan Green, et al.. (2014). Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers. European Respiratory Journal. 44(Suppl 58). 3411–3411. 4 indexed citations

16.

Boyce, Malcolm, et al.. (2012). Single oral doses of netazepide ( YF 476), a gastrin receptor antagonist, cause dose‐dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Alimentary Pharmacology & Therapeutics. 36(2). 181–189. 28 indexed citations

17.

Calder, Nicole, Malcolm Boyce, John Posner, & David Sciberras. (2003). Clinical pharmacology studies in UK Phase 1 units: an AHPPI survey 1999–2000. British Journal of Clinical Pharmacology. 57(1). 76–79. 3 indexed citations

18.

Moore, Katy H. P., Lindsey Cass, Nigel Dallow, et al.. (2001). Pharmacokinetics and Tolerability of GW420867X, a Nonnucleoside Reverse Transcriptase Inhibitor, following Single Escalating Doses in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 41(10). 1098–1105. 1 indexed citations

19.

Marshall, Ernest, Anthony Howell, R Powles, et al.. (1998). Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1α (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. European Journal of Cancer. 34(7). 1023–1029. 13 indexed citations

20.

Conroy, Thierry, P Cappelaere, Michel Fabbro, et al.. (1994). Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5-HT3 Antagonist, in Cancer Patients Treated with Cisplatin. American Journal of Clinical Oncology. 17(2). 97–102. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact